Abstract:Mycobacterium tuberculosis ( M . tb ), the causative agent of tuberculosis (TB), is a leading global cause of death from infectious disease. Biofilms are increasingly recognized as a relevant growth form during M . tb infection and may impede treatment by enabling bacterial drug and immune tolerance. M . tb has a complicated regulatory network that has been well-characterized for many relevant disease states, including dormancy and hypoxia. However, despite its importance, our knowledge of the genes and pathways involved in biofilm formation is limited. Here we characterize the biofilm transcriptomes of fully virulent clinical isolates and find that the regulatory systems underlying biofilm growth vary widely between strains and are also distinct from regulatory programs associated with other environmental cues. We used experimental evolution to investigate changes to the transcriptome during adaptation to biofilm growth and found that the application of a uniform selection pressure resulted in loss of strain-to-strain variation in gene expression, resulting in a more uniform biofilm transcriptome. The adaptive trajectories of transcriptomes were shaped by the genetic background of the M . tb population leading to convergence on a sub-lineage specific transcriptome. We identified widespread upregulation of non-coding RNA (ncRNA) as a common feature of the biofilm transcriptome and hypothesize that ncRNA function in genome-wide modulation of gene expression, thereby facilitating rapid regulatory responses to new environments. These results reveal a new facet of the M . tb regulatory system and provide valuable insight into how M . tb adapts to new environments. Understanding mechanisms of resistance and tolerance in Mycobacterium tuberculosis ( M . tb ) can help us develop new treatments that capitalize on M . tb 's vulnerabilities. Here we used transcriptomics to study both the regulation of biofilm formation in clinical isolates as well as how those regulatory systems adapt to new environments. We find that closely related clinical populations have diverse strategies for growth under biofilm conditions, and that genetic background plays a large role in determining the trajectory of evolution. These results have implications for future treatment strategies that may be informed by our knowledge of the evolutionary constraints on strain(s) from an individual infection. This work provides new information about the mechanisms of biofilm formation in M . tb and outlines a framework for population level approaches for studying bacterial adaptation.

Mycobacterium Tuberculosis Biofilm Matrix and Potential Drug Targets and Treatment Strategies

Mycobacterial Biofilm: Mechanisms, Clinical Problems, and Treatments

Mycobacterial biofilms: Understanding the genetic factors playing significant role in pathogenesis, resistance and diagnosis

Mycobacterial biofilms: A therapeutic target against bacterial persistence and generation of antibiotic resistance

Regulation of Mycobacterium biofilm development and novel measures against antibiotics resistance

Gene expression profile analysis and target gene discovery of Mycobacterium tuberculosis biofilm

The past, present and future of tuberculosis treatment.

Adaptation of the Mycobacterium tuberculosis transcriptome to biofilm growth

Biofilm Formation in Mycobacterial Genus; Mechanism of Biofilm Formation and Anti-Mycobacterial Biofilm Agents

Biofilm formation in the lung contributes to virulence and drug tolerance of Mycobacterium tuberculosis

The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development

Three-dimensional low shear culture of Mycobacterium bovis BCG induces biofilm formation and antimicrobial drug tolerance

Metabolic Versatility of Mycobacterium tuberculosis during Infection and Dormancy

Protein Targets for Structure-Based Anti-Mycobacterium Tuberculosis Drug Discovery

Emerging advances in identifying signal transmission molecules involved in the interaction between Mycobacterium tuberculosis and the host

Recent Progress in the Development of Novel Mycobacterium Cell Wall Inhibitor to Combat Drug-Resistant Tuberculosis

Structural Biology and Inhibition of the Mtb Cell Wall Glycoconjugates Biosynthesis on the Membrane

Protein targets for structure-based anti- Mycobacterium tuberculosis drug discovery

Contingencies in biofilm adaptation of Mycobacterium tuberculosis

Genes and Regulatory Networks Involved in Persistence of Mycobacterium Tuberculosis

Understanding the intricacies of microbial biofilm formation and its endurance in chronic infections: a key to advancing biofilm-targeted therapeutic strategies